Baidu
map

Ann Oncol:绝经后乳腺癌女性:芳香化酶抑制剂增加结直肠癌风险?

2018-04-27 张琪 环球医学网

发表在《Ann Oncol》的一项由加拿大科学家进行的研究,考察了绝经后乳腺癌女性芳香化酶抑制剂(AI)使用与结直肠癌风险之间的相关性。

发表在《Ann Oncol》的一项由加拿大科学家进行的研究,考察了绝经后乳腺癌女性芳香化酶抑制剂(AI)使用与结直肠癌风险之间的相关性。

背景:一项针对绝经后乳腺癌女性的大型试验报告,作为辅助治疗,与他莫昔芬相比,AIs的结直肠癌事件不平衡。该一非预期的信息是在随机化的3年内观察到的。至今,还没有观察性研究考察在临床实践的自然条件下这一重要的安全性问题。因此,本研究旨在确定与他莫昔芬相比,AIs是否与绝经后乳腺癌女性结直肠癌风险增加相关。

患者和方法:使用英国临床实践研究数据链,研究者鉴别出1996年1月1日~2015年9月30日的乳腺癌患者。患者入组标准为:至少55岁,新接受AIs或他莫昔芬治疗,随访至2016年9月30日。高维倾向得分校正的Cox成比例风险模型用于评估与他莫昔芬相比,与AIs相关的结直肠癌总体风险比(HRs)、累积使用时间HR、初始使用以来的时间HR及95% 置信区间(CIs)。出于潜伏期的考虑,所有暴露都延迟1年。

结果:总共9701例和8893例患者初始AIs和他莫昔芬作为一线激素治疗(分别中位随访2.4和2.9年)。与他莫昔芬相比,AIs与结直肠癌风险增加不相关(两组发病率为150例/100000人-年;校正HR:0.90;95% CI,0.53~1.52)。相似的,无证据显示与累积使用时间(P异质性=0.54)和自初始用药的时间(P异质性=0.66)具有相关性。

结论:在这项首个基于人群的研究中,AIs的使用与结直肠癌风险增加不相关。这些结果为利益相关者提供了保证。

原始出处:
Khosrow-Khavar F, Yin H, Barkun A, et al.Aromatase inhibitors and the risk of colorectal cancer in postmenopausal women with breast cancer.Ann Oncol. 2018 Mar 1;29(3):744-748. doi: 10.1093/annonc/mdx822.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1705342, encodeId=5cf91e05342a2, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 10:05:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061739, encodeId=46d02061e390f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jul 03 09:05:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865426, encodeId=6ce2186542610, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 30 00:05:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851700, encodeId=06c51851e0076, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 31 19:05:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257153, encodeId=06ce125e15310, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360813, encodeId=e13d1360813f6, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453107, encodeId=dd0b145310e43, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631580, encodeId=31df1631580b9, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310100, encodeId=bf8d310100b1, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:24 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1705342, encodeId=5cf91e05342a2, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 10:05:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061739, encodeId=46d02061e390f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jul 03 09:05:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865426, encodeId=6ce2186542610, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 30 00:05:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851700, encodeId=06c51851e0076, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 31 19:05:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257153, encodeId=06ce125e15310, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360813, encodeId=e13d1360813f6, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453107, encodeId=dd0b145310e43, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631580, encodeId=31df1631580b9, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310100, encodeId=bf8d310100b1, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:24 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-07-03 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=1705342, encodeId=5cf91e05342a2, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 10:05:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061739, encodeId=46d02061e390f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jul 03 09:05:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865426, encodeId=6ce2186542610, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 30 00:05:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851700, encodeId=06c51851e0076, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 31 19:05:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257153, encodeId=06ce125e15310, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360813, encodeId=e13d1360813f6, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453107, encodeId=dd0b145310e43, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631580, encodeId=31df1631580b9, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310100, encodeId=bf8d310100b1, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:24 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-08-30 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1705342, encodeId=5cf91e05342a2, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 10:05:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061739, encodeId=46d02061e390f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jul 03 09:05:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865426, encodeId=6ce2186542610, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 30 00:05:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851700, encodeId=06c51851e0076, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 31 19:05:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257153, encodeId=06ce125e15310, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360813, encodeId=e13d1360813f6, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453107, encodeId=dd0b145310e43, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631580, encodeId=31df1631580b9, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310100, encodeId=bf8d310100b1, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:24 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2019-01-31 jklm09
  5. [GetPortalCommentsPageByObjectIdResponse(id=1705342, encodeId=5cf91e05342a2, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 10:05:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061739, encodeId=46d02061e390f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jul 03 09:05:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865426, encodeId=6ce2186542610, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 30 00:05:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851700, encodeId=06c51851e0076, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 31 19:05:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257153, encodeId=06ce125e15310, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360813, encodeId=e13d1360813f6, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453107, encodeId=dd0b145310e43, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631580, encodeId=31df1631580b9, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310100, encodeId=bf8d310100b1, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:24 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1705342, encodeId=5cf91e05342a2, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 10:05:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061739, encodeId=46d02061e390f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jul 03 09:05:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865426, encodeId=6ce2186542610, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 30 00:05:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851700, encodeId=06c51851e0076, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 31 19:05:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257153, encodeId=06ce125e15310, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360813, encodeId=e13d1360813f6, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453107, encodeId=dd0b145310e43, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631580, encodeId=31df1631580b9, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310100, encodeId=bf8d310100b1, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:24 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1705342, encodeId=5cf91e05342a2, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 10:05:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061739, encodeId=46d02061e390f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jul 03 09:05:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865426, encodeId=6ce2186542610, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 30 00:05:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851700, encodeId=06c51851e0076, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 31 19:05:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257153, encodeId=06ce125e15310, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360813, encodeId=e13d1360813f6, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453107, encodeId=dd0b145310e43, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631580, encodeId=31df1631580b9, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310100, encodeId=bf8d310100b1, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:24 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1705342, encodeId=5cf91e05342a2, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 10:05:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061739, encodeId=46d02061e390f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jul 03 09:05:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865426, encodeId=6ce2186542610, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 30 00:05:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851700, encodeId=06c51851e0076, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 31 19:05:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257153, encodeId=06ce125e15310, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360813, encodeId=e13d1360813f6, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453107, encodeId=dd0b145310e43, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631580, encodeId=31df1631580b9, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310100, encodeId=bf8d310100b1, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:24 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-29 zxxiang
  9. [GetPortalCommentsPageByObjectIdResponse(id=1705342, encodeId=5cf91e05342a2, content=<a href='/topic/show?id=7b9de87144b' target=_blank style='color:#2F92EE;'>#结直肠癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78714, encryptionId=7b9de87144b, topicName=结直肠癌风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c54a30977679, createdName=lfyang, createdTime=Fri Jan 11 10:05:00 CST 2019, time=2019-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061739, encodeId=46d02061e390f, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Tue Jul 03 09:05:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865426, encodeId=6ce2186542610, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Aug 30 00:05:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851700, encodeId=06c51851e0076, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jan 31 19:05:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257153, encodeId=06ce125e15310, content=<a href='/topic/show?id=cdfce8879b1' target=_blank style='color:#2F92EE;'>#绝经#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78879, encryptionId=cdfce8879b1, topicName=绝经)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360813, encodeId=e13d1360813f6, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453107, encodeId=dd0b145310e43, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1631580, encodeId=31df1631580b9, content=<a href='/topic/show?id=6395e888343' target=_blank style='color:#2F92EE;'>#绝经后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78883, encryptionId=6395e888343, topicName=绝经后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32b921798518, createdName=zxxiang, createdTime=Sun Apr 29 01:05:00 CST 2018, time=2018-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=310100, encodeId=bf8d310100b1, content=学习了.长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Apr 28 12:35:24 CST 2018, time=2018-04-28, status=1, ipAttribution=)]
    2018-04-28 1ddf0692m34(暂无匿称)

    学习了.长知识

    0

相关资讯

Brit J Cancer:绝经后妇女饮酒与雌激素代谢产物之间的相关性分析!

由此可见,绝经后妇女饮酒量与雌激素水平之间存在相关性,但与雌激素代谢物的浓度无关,提示可能受到MHT和饮酒类型的影响。

Plos One:绝经激素疗法或能保护女性心脏

3月8日,在线发表于《Plos One》杂志上的一项研究显示,接受绝经激素疗法(MHT)的女性,心脏会得到更好的保护,从而使其具有较低的心衰风险。

J Thromb Haemost:绝经后妇女血管舒缩症状与静脉血栓形成的风险!

由此可见,尽管在发表的研究中血管舒缩症状与其他心血管事件的风险有关,但该研究的发现并不表明血管舒缩症状是VT风险的一个标志。

JCEM:绝经后抗骨质疏松症治疗会引起循环微小RNA改变!

由此可见,循环中miRs受特立帕肽和狄诺塞麦治疗的影响具有差异。采用特立帕肽治疗会影响到与Runx-2(miR-33)及DKK-1(miR-133)基因表达相关的miRs相对表达。

Osteoporos Int:绝经后骨质疏松女性:双磷酸盐类“药物假期”增加骨折风险?

2017年12月,发表在《Osteoporos Int》的一项由法国科学家进行的回顾性分析, 考察了绝经后骨质疏松女性中,双磷酸盐(BPs)类药物假期治疗对临床骨折风险的影响。

JCEM:绝经后妇女高雄激素与动脉粥样硬化和心血管疾病风险分析!

由此可见,绝经后较高的雄激素水平与CVD风险增加无关。多囊卵巢综合征患者的心血管健康可能比预期的要好。

Baidu
map
Baidu
map
Baidu
map